Mannitol-Infusionslösung 20 (Mannitol)

Mannitol remains largely unmetabolized after intravenous administration, establishing an osmotic gradient across cell membranes and within the renal tubules. This gradient pulls water from intracellular and interstitial spaces into the vascular compartment and then into the urine, thereby decreasing swelling in the brain and eye and promoting diuresis.

The specific dose and infusion rate of Mannitol-Infusionslösung 20 are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Healthcare professionals tailor the regimen to achieve the desired reduction in pressure or diuretic effect while monitoring safety parameters.

Safety data for mannitol in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mannitol is a non‑metabolizable sugar alcohol commonly used for its rapid osmotic effect, whereas alternatives such as hypertonic saline or glycerol may have different electrolyte profiles and onset times. Mannitol’s advantage lies in its predictable renal excretion and ability to lower both intracranial and intra‑ocular pressures effectively.

Mannitol-Infusionslösung 20 should be stored at room temperature, below 25 °C, in its original packaging to protect from moisture and light. The solution must be kept in a clean, dry environment and inspected for particulate matter before use.

The product is administered intravenously by slow infusion through a calibrated infusion set. Healthcare professionals calculate the infusion rate based on the prescribed dose, monitor the patient’s vital signs, and adjust the rate as needed to achieve therapeutic goals while observing for adverse reactions.

Serious risks include acute renal failure worsening, severe electrolyte disturbances (especially hyponatremia or hyperkalemia), pulmonary edema from fluid overload, and rare anaphylactic reactions. Continuous monitoring of renal function, electrolytes, and fluid balance is essential to mitigate these risks.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial bleeding, uncontrolled heart failure, or severe renal impairment where excretion is compromised. Clinicians should evaluate each patient’s medical history before initiating therapy.